Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links
PERRIGO INFANT ORAL DROPS RECALL

Perrigo recalls infants’ oral drops in US

 

BY OUR PHARMA  CORRESPONDENT

5 August, 2005: The Perrigo Company is voluntarily recalling all lots of concentrated infants’ drops that are packaged with a dosing syringe bearing only a “1.6 mL” mark containing acetaminophen, acetaminophen, dextromethorphan HBr, and pseudoephedrine HCl, or dextromethorphan HBr, and pseudoephedrine HCl, a US FDA release said.

The products are being recalled because the oral dosing syringe enclosed with these products is not marked so as to accurately measure doses less than 1.6 mL when prescribed by physicians for infants younger than 2 years and weighing less than 24 pounds. Until recently these products were provided with a dropper, not the oral dosing syringe, and the dropper had two markings on it (“0.4 mL” and “0.8 mL”).

The dosing syringe may be confusing in determining the proper dose for infants under 2 years of age as directed by a doctor and could lead to improper dosing, including overdosing. The following products are being recalled to the retail level:

-Cherry Flavor Infant Pain Reliever 160 mg Acetaminophen (0.5oz. and 1.0oz)

-Grape Flavor Infant Pain Reliever 160 mg Acetaminophen (0.5oz. and 1.0oz)

-Cherry Flavor Cough and Cold Infant Drops (0.5oz)

-Cherry Flavor Decongestant and Cough Infant Drops (0.5oz)

The directions on the bottle and carton labeling for infants ages 2-3 years and weighing 24-35 pounds allow safe and effective dosing for this age and weight group. However, these products are also intended for use by infants younger than 2 years and weighing less than 24 pounds. The labeling directs consumers to ask a doctor for dosing directions for this age and weight group.

The single mark on the current syringe along with the changeover from the dropper to this syringe has caused some confusion among consumers and health-care professionals and may lead to improper dosing. Taking more than the recommended dose (overdose) of acetaminophen may cause liver damage. The products, however, are safe and effective when accurately dosed. Parents or caregivers who have questions should discuss with their doctor how to accurately determine the proper dose.

The recalled products were sold nationally at retail chains under the following store-brand labels: American Fare, Best Choice, Brooks, Berkley & Jensen, CVS, Dollar General, Eckerd, Equaline, Equate, Family Dollar, Food Lion, Good Neighbor, GoodSense, Healthy Generations, Health Pride, Hy-Vee, Kroger, Leader, Longs, Major, Medicine Shoppe, Meijer, Parklane, Publix, Rite Aid, Safeway, Shop Rite, Sunmark, Target, Today’s Health, Top Care, Walgreen, Western Family, and Winn Dixie.

Based in Allegan, Michigan, USA, Perrigo is a leading global healthcare supplier and the world’s largest manufacturer of the over-the-counter (OTC) pharmaceutical and nutritional products sold by food, drug, mass merchandise, dollar store and club store retailers under their own labels. Recently, Perrigo acquired (March 17, 2005) Agis Industries in an effort to expedite the launch of its generic strategy. The collective sales for Agis and Perrigo exceed $1.3 billion dollars. The company operates manufacturing and logistics faculties in the United States, Israel, United Kingdom, Mexico, and Germany, employing over 6,000 people.

BY OUR PHARMA  CORRESPONDENT

Pharma News Headlines

Cancer News

Cardiac News

US FDA News

Pharma industry news

LATEST UPDATES

Heart disease deaths more among New Yorkers

Pfizer to offer drugs risk/benefit summary to consumers 

Merck lied to public on Vioxx: lawyer tells jurors

Novartis acquires rights of kidney dialysis drug from SeBo

J&J's Concerta approved treatment of ADHD in teenagers in Canada

US FDA stalls Roche’ Accutane use in pregnancy

Novo Nordisk, Eli Lilly remove insulin products from Australia

British drug supply chain safety questioned after another fake Lipitor find

Wyeth starts support programme for Effexor patients

P&G’s Actonel with Calcium approved for osteoporosis

Pozen gets patent on pain management product

Genmab studies new drug for rheumatoid arthritis

Painkillers may increase blood pressure: study

Nektar buys out Aerogen for $32 m

Predix records positive data on anxiety drug

Insmed files against Increlex approval

Hepatitis A vaccine for kids approved in US

Psoriasis drug data positive: Cytochroma

Novo Nordisk’s 24-hour acting insulin Levemir gets US FDA okay

US FDA approves Teva's generic for osteoporosis 

Pfizer files NDA for Sutent in US

BioVeris licenses Baxter's vaccine portfolio

TheraQuest receives 2nd Orphan Drug status for neuralgia drug

Real-time glucose monitoring device approved in US

Halozyme gets FDA nod for bladder cancer therapy

Migenix to commence phase 2b studies in hep C therapy

Barr gets US FDA okay for clonazepam tabs

Anorexia drug study results positive: Par

GlaxoSmithKline begins phase III trials of new HIV drug

Ranbaxy's 7 anti retrovirals included in WHO list

FDA tightens restrictions on acne drug

Voglibose tabs launched in Japan

Remicade researcher gifts $ 105m to NYU

Par loses ondansetron case to GSK

Mistral starts clinical studies for generic

Carl Icahn sells Mylan shares

Florida sues Mylan, Teva and Watson

Dey and Connecticut settle pricing dispute

Germany set to stop rabies crossing borders

Office to review DTC drug advertisements in US

British docs to be trained in communication, safety

FDA okays acrylic lens for cataract patients 

Corautus to go ahead with angina drug studies 

Americans turn the low-fat way

Chemicals in plastics pose danger

US committee probes doctors’ complicity with Wall Street analysts

Meda buys out rival Viatris

US FDA nod for new levofloxacin regimen to treat acute bacterial sinusitis

Pozen files for new migraine treatment

New therapy for pancreatic cancer under review

New device inducing blood flow to heart granted US patent

NIH announces grants for faster, cheaper DNA sequencing

DOV starts phase III trial of pain drug in US

Alcohol linked cancers: Acetaldehyde in spot light

Hypertension `just above normal’ too risky

Gene causes infertility drugs go awry: study

China’s pig flu outbreak

Cardiac Science-Defibtech lawsuit settled

Peregrine starts Phase-1 anti-viral trial of Tarvacin

Dr. Reddy's launches immune booster for children

Lupin in pact with Kyowa of Japan

Bird flu vaccine may work in humans: US researchers

 

 

Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

Latest updates    Contact Us - Feedback    About Us